banner
EGFR-HER2 inhibitor PD168393, Purity ≥98%
Inquiry

Cat. No.: X24-05-ZQ632

EGFR-HER2 inhibitor PD168393, Purity ≥98%

Synonym: 194423-15-9; PD-168393; PD 168393; EGFR-HER2 inhibitor

  • CAS Number: 194423-15-9
  • Compound CID: 4708
img
Product Size
5 mg; 10 mg; 50 mg
Price
Datasheet
MSDS
Properties
Description
PD168393, soluble in DMSO and insoluble in ethanol and water, is a compound that blocks the activity of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), both of which are involved in driving the growth and proliferation of certain types of cancer cells. It targets EGFR, FGFR, Insulin Receptor, and PDGFR.
Molecular Weight
369.22
Molecular Formula
C17H13BrN4O
Targets
EGFR: 0.70 nM; FGFR: >50 μM; Insulin Receptor: >50 μM; PDGFR: >50 μM
Form
Lyophilized powder
Purity
≥98%
Solubility
DMSO: 72 mg/mL (195 mM); Water: Insoluble; Ethanol: Insoluble
Identity
Confirmed by NMR/HPLC/MS.
Applications
PD168393 is used to inhibit EGFR tyrosine kinase in research on cancer cell proliferation and survival pathways.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0